지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 191 - 196 (6page)
이용수
초록· 키워드
오류제보하기
Background/Aims: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods: We performed a single-arm, multicenter prospective study. Twenty-one chronic hemodialysis patients with HCV infection were prospectively enrolled from February 2016 to April 2017. We evaluated the virological responses at weeks 4, 12, and 24 (end of treatment [EOT]) and the sustained virological response at 12 weeks after the EOT (SVR12). The tolerability and safety of the drugs were also assessed. Results: None of the 20 patients had the NS5A resistance-associated variant (NS5A RAV), and one patient was indeterminate for the NS5A RAV. Seventeen patients (80%) completed the 24 weeks of treatment with DCV and ASV. Four patients discontinued the study prior to week 12. In an intention-to-treat analysis, the SVR12 was 76.1%. In a per-protocol analysis, patients who completed DCV and ASV treatment achieved an SVR12 of 100%. DCV and ASV were well tolerated by the majority of patients. Three patients discontinued treatment due to adverse events (AEs) including dizziness, dyspnea, and neutropenia. The patient with indeterminate NS5A RAV showed viral breakthrough and discontinued treatment. Conclusions: DCV and ASV combination therapy in chronic hemodialysis patients with HCV infection achieved a high SVR12 rate with few AEs. To maximize the SVR12 rate, it is important to identify candidates by baseline RAV testing. Close monitoring of the safety and tolerability of DCV and ASV may be necessary in HCV-infected patients on hemodialysis. (ClinicalTrials.gov ID NCT02580474)
목차
등록된 정보가 없습니다.
참고문헌 (26)
참고문헌 신청
Westbrook RH / 2014 / Natural history of hepatitis C / J Hepatol 61(1 Suppl):S58~S68
Mohd Hanafiah K / 2013 / Global epidemiology of hepatitis C virus infection : new estimates of age-specific antibody to HCV seroprevalence / Hepatology 57:1333~1342
Johnson DW / 2009 / Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries : analysis of registry data / Nephrol Dial Transplant 24:1598~1603
진동찬 / 2016 / Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients / Kidney Research and Clinical Practice 35(4):204~211
Jadoul M / 2004 / The changing epidemiology of hepatitis C virus(HCV)infection in haemodialysis : European multicentre study / Nephrol Dial Transplant 19:904~909
Mohd Hanafiah K / 2013 / Global epidemiology of hepatitis C virus infection : new estimates of age-specific antibody to HCV seroprevalence / Hepatology 57:1333~1342
Johnson DW / 2009 / Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries : analysis of registry data / Nephrol Dial Transplant 24:1598~1603
진동찬 / 2016 / Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients / Kidney Research and Clinical Practice 35(4):204~211
Jadoul M / 2004 / The changing epidemiology of hepatitis C virus(HCV)infection in haemodialysis : European multicentre study / Nephrol Dial Transplant 19:904~909
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
Clinical and Molecular Hepatology
2016 .01
-
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Clinical and Molecular Hepatology
2017 .01
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
-
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
Journal of Korean Medical Science
2019 .01
-
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
2017 .01
-
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
Gut and Liver
2020 .01
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
고령의 만성 C형 간염 환자에서 Daclatasvir와 Asunaprevir 병용 요법의 유효성 및 안전성 평가
병원약사회지
2018 .01
-
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
Clinical and Molecular Hepatology
2019 .01
-
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
Gut and Liver
2018 .01
-
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
Clinical and Molecular Hepatology
2018 .01
-
Treatment Outcomes of HCV Infection in People Living with HIV: A Case Series from a Single Center in Korea
Infection and Chemotherapy
2024 .09
-
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
Gut and Liver
2021 .11
-
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C
Journal of Korean Medical Science
2016 .01
-
Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
Gut and Liver
2018 .01
-
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Gut and Liver
2016 .01
-
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
Gut and Liver
2015 .01
-
Hepatitis C Viral Infection in Children: Updated Review
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Cost-effectiveness of chronic hepatitis C screening and treatment
Clinical and Molecular Hepatology
2022 .04
-
말기 신 질환자의 혈액투석경험에 관한 현상학적 접근
재활간호학회지
2018 .06
이 논문의 저자 정보
최근 본 자료
댓글(0)
0